)
Autolus Therapeutics (AUTL) investor relations material
Autolus Therapeutics Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Company overview and business model
Commercial-stage biopharmaceutical company focused on next-generation T cell therapies for cancer and autoimmune diseases, leveraging proprietary T cell programming technologies.
Lead product AUCATZYL (obe-cel) approved by FDA in November 2024 for adult relapsed/refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL); commercial launches in the US (Jan 2025) and UK (Jan 2026).
Obe-cel is also in development for pediatric B-ALL, B-NHL, and autoimmune indications, with ongoing clinical trials and promising early data.
Manufacturing centralized at the Nucleus facility in Stevenage, UK, with Cardinal Health as US distribution partner.
Financial performance and metrics
Financial statements for the year ended December 31, 2025, audited by Ernst & Young LLP, are incorporated by reference.
Company voluntarily files detailed periodic reports on US domestic issuer forms, providing extensive financial disclosures.
Use of proceeds and capital allocation
Will not receive proceeds from the resale of ADSs by the selling securityholder; proceeds from warrant exercise ($1.9314 per ADS) will be received if exercised for cash.
Registration costs borne by the company; selling securityholder pays underwriting fees, commissions, and certain legal expenses.
- Strong revenue growth, clinical success, and pipeline expansion drive future value.AUTL
Corporate presentation - Q2 2026 revenue surged 119% year-over-year, with gross margin at 55% and guidance raised.AUTL
Q2 2026 - Obe-cel delivers durable remissions in adult ALL, with persistence driving long-term outcomes.AUTL
Status Update - AUCATZYL's U.S. launch exceeds expectations, with expansion into Europe and autoimmune indications advancing.AUTL
Goldman Sachs 46th Annual Global Healthcare Conference - Expanding CAR T-cell therapy demonstrates robust efficacy, safety, and broadening market reach.AUTL
H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - Strong commercial growth and pipeline progress, with high remission rates and expanding indications.AUTL
46th Annual William Blair Growth Stock Conference - Lead CAR-T therapy sees robust growth, margin gains, and broadening clinical impact.AUTL
Jefferies Global Healthcare Conference 2026 - Obe-cel advances in B-ALL and lupus nephritis, with pivotal trials and EU/UK reviews ahead.AUTL
Status Update - AUCATZYL's US launch drove $9M Q1 revenue, UK approval, and pivotal trials in LN and MS ahead.AUTL
Q1 2025
Next Autolus Therapeutics earnings date
Next Autolus Therapeutics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)